Use a survival model to correlate single-nucleotide polymorphisms of DNA repair genes with radiation dose-response in patients with non-small cell lung cancer

被引:16
作者
Jin, Jian-Yue [1 ]
Wang, Weili [2 ]
Ten Haken, Randall K. [2 ]
Chen, Jie [3 ]
Bi, Nan [2 ]
Sadek, Ramses [3 ]
Zhang, Hong [1 ]
Lawrence, Theodore S. [2 ]
Kong, Feng-Ming [1 ]
机构
[1] Georgia Regents Univ, Dept Radiat Oncol, Augusta, GA 30912 USA
[2] Univ Michigan, Dept Radiat Oncol, Ann Arbor, MI 48109 USA
[3] Georgia Regents Univ, Dept Biostat & Epidemiol, Augusta, GA USA
关键词
Personalized radiotherapy; Single-nucleotide-polymorphisms (SNPs); Biomarker; ERCC1 and ERCC2; Dose survival model; Radiosensitivity; PLATINUM-BASED CHEMOTHERAPY; CONFORMAL RADIOTHERAPY; XPD POLYMORPHISMS; ASSOCIATION; TOXICITY; IRRADIATION; COMBINATION; ESCALATION; VOLUME; NSCLC;
D O I
10.1016/j.radonc.2015.07.024
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: This study utilizes a survival model and clinical data with various radiation doses from prospective trials to determine radiation dose-response parameters, such as radiosensitivity, and identify single-nucleotide-polymorphism (SNP) biomarkers that can potentially predict the dose response and guide personalized radiotherapy. Methods: The study included 92 consecutive stage-III NSCLC patients with doses varying from 60 to 91 Gy. Logistic regression analysis of survival varying with SNP genotype and radiation dose was used to screen candidates for dose-response analysis. The dose-response parameter, represented by D-50, was derived by fitting survival data into a model that takes into account both tumor control and treatment mortality. A candidate would be considered as a predictor if the 90% confident intervals (90% CIs) of D-50 for the 2 groups stratified by the SNP genotype were separated. Results: One SNP-signature (combining ERCC2:rs238406 and ERCC1:rs11615) was found to predict dose-response. D-50 values are 63.7 (90% CI: 53.5-66.3) Gy and 76.1 (90% CI: 71.3, 84.6) Gy for the 2 groups stratified by the genotypes. Using this biomarker-based model, a personalized dose prescription may be generated to improve 2-year survival from similar to 50% to 85% and similar to 3% to 73% for hypothetical sensitive and resistant patients, respectively. Conclusions: We have developed a survival model that may be used to identify genomic markers, such as ERCC1/2 SNPs, to predict radiation dose-response and potentially guide personalized radiotherapy. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:77 / 82
页数:6
相关论文
共 29 条
  • [1] ERCC1-XPF endonuclease facilitates DNA double-strand break repair
    Ahmad, Anwaar
    Robinson, Andria Rasile
    Duensing, Anette
    van Drunen, Ellen
    Beverloo, H. Berna
    Weisberg, David B.
    Hasty, Paul
    Hoeijmakers, Jan H. J.
    Niedernhofer, Laura J.
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 2008, 28 (16) : 5082 - 5092
  • [2] Functional characterization of Polymorphisms in DNA repair genes using cytogenetic challenge assays
    Au, WW
    Salama, SA
    Sierra-Torres, CH
    [J]. ENVIRONMENTAL HEALTH PERSPECTIVES, 2003, 111 (15) : 1843 - 1850
  • [3] The complex relationship between lung tumor volume and survival in patients with non-small cell lung cancer treated by definitive radiotherapy: A prospective, observational prognostic factor study of the Trans-Tasman Radiation Oncology Group (TROG 99.05)
    Ball, David L.
    Fisher, Richard J.
    Burmeister, Bryan H.
    Poulsen, Michael G.
    Graham, Peter H.
    Penniment, Michael G.
    Vinod, Shalini K.
    Krawitz, Hedley E.
    Joseph, David J.
    Wheeler, Greg C.
    McClure, Bev E.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2013, 106 (03) : 305 - 311
  • [4] Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study
    Bradley, Jeffrey D.
    Paulus, Rebecca
    Komaki, Ritsuko
    Masters, Gregory
    Blumenschein, George
    Schild, Steven
    Bogart, Jeffrey
    Hu, Chen
    Forster, Kenneth
    Magliocco, Anthony
    Kavadi, Vivek
    Garces, Yolanda I.
    Narayan, Samir
    Iyengar, Puneeth
    Robinson, Cliff
    Wynn, Raymond B.
    Koprowski, Christopher
    Meng, Joanne
    Beitler, Jonathan
    Gaur, Rakesh
    Curran, Walter, Jr.
    Choy, Hak
    [J]. LANCET ONCOLOGY, 2015, 16 (02) : 187 - 199
  • [5] Differential toxicity biomarkers for irinotecan- and oxaliplatin-containing chemotherapy in colorectal cancer
    Cortejoso, Lucia
    Garcia, Maria I.
    Garcia-Alfonso, Pilar
    Gonzalez-Haba, Eva
    Escolar, Fernando
    Sanjurjo, Maria
    Lopez-Fernandez, Luis A.
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (06) : 1463 - 1472
  • [6] Association of DNA repair and steroid metabolism gene polymorphisms with clinical late toxicity in patients treated with conformal radiotherapy for prostate cancer
    Damaraju, S
    Murray, D
    Dufour, J
    Carandang, D
    Myrehaug, S
    Fallone, G
    Field, C
    Greiner, R
    Hanson, J
    Cass, CE
    Parliament, M
    [J]. CLINICAL CANCER RESEARCH, 2006, 12 (08) : 2545 - 2554
  • [7] Mice with skin-specific DNA repair gene (Ercc1) inactivation are hypersensitive to ultraviolet irradiation-induced skin cancer and show more rapid actinic progression
    Doig, J.
    Anderson, C.
    Lawrence, N. J.
    Selfridge, J.
    Brownstein, D. G.
    Melton, D. W.
    [J]. ONCOGENE, 2006, 25 (47) : 6229 - 6238
  • [8] Therapeutic immunization and local low-dose tumor irradiation, a reinforcing combination
    Draghiciu, Oana
    Walczak, Mateusz
    Hoogeboom, Baukje Nynke
    Franken, Kees L. M. C.
    Melief, Kees J. M.
    Nijman, Hans W.
    Daemen, Toos
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2014, 134 (04) : 859 - 872
  • [9] Eric JHall Amato J Giaccia., 2006, Radiobiology for the Radiologist
  • [10] Non-Small Cell Lung Cancer, Version 2.2013 Featured Updates to the NCCN Guidelines
    Ettinger, David S.
    Akerley, Wallace
    Borghaei, Hossein
    Chang, Andrew C.
    Cheney, Richard T.
    Chirieac, Lucian R.
    D'Amico, Thomas A.
    Demmy, Todd L.
    Govindan, Ramaswamy
    Grannis, Frederic W., Jr.
    Grant, Stefan C.
    Horn, Leora
    Jahan, Thierry M.
    Komaki, Ritsuko
    Kong, Feng-Ming
    Kris, Mark G.
    Krug, Lee M.
    Lackner, Rudy P.
    Lennes, Inga T.
    Loo, Billy W., Jr.
    Martins, Renato
    Otterson, Gregory A.
    Patel, Jyoti D.
    Pinder-Schenck, Mary C.
    Pisters, Katherine M.
    Reckamp, Karen
    Riely, Gregory J.
    Rohren, Eric
    Shapiro, Theresa A.
    Swanson, Scott J.
    Tauer, Kurt
    Wood, Douglas E.
    Yang, Stephen C.
    Gregory, Kristina
    Hughes, Miranda
    [J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2013, 11 (06): : 645 - 653